Department of Pathology, Qiqihar Medical University, Qiqihar, China.
Department of General Surgery, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
J Clin Lab Anal. 2021 Jan;35(1):e23560. doi: 10.1002/jcla.23560. Epub 2020 Dec 23.
Aberrant levels of circulating microRNAs (miRNAs) are potential biomarkers in papillary thyroid carcinoma (PTC) diagnosis and therapy. The aim of this study was to evaluate serum exosomal miR-29a expression as a non-invasive biomarker for PTC diagnosis and prognosis.
Quantitative reverse transcription polymerase chain reaction was applied to measure serum exosomal miR-29a expression levels in blood samples of 119 patients with PTC and 100 control subjects.
Serum exosomal miR-29a expression levels were significantly decreased in PTC cases. In addition, receiver operating characteristic (ROC) analysis revealed serum exosomal miR-29a could well differentiate PTC from normal controls. Moreover, serum exosomal miR-29a levels increased progressively and significantly 30 days and 90 days after surgery. Furthermore, PTC patients with lower serum exosomal miR-29a expression had higher risk of recurrence. Decreased serum exosomal miR-29a expression was significantly associated with worse clinical variables including tumor size, extrathyroidal extension, and TNM stage, as well as shorter survival. Finally, both univariate and multivariate identified serum exosomal miR-29a as an independent prognostic indicator for overall survival.
These results demonstrated that serum exosomal miR-29a might serve as a potential biomarker for PTC diagnosis and prognosis.
循环 microRNAs（miRNAs）水平异常是甲状腺乳头状癌（PTC）诊断和治疗的潜在生物标志物。本研究旨在评估血清外泌体 miR-29a 表达作为 PTC 诊断和预后的非侵入性生物标志物。
采用定量逆转录聚合酶链反应（qRT-PCR）测量 119 例 PTC 患者和 100 例对照者血液样本中的血清外泌体 miR-29a 表达水平。
PTC 病例血清外泌体 miR-29a 表达水平明显降低。此外，受试者工作特征（ROC）分析显示血清外泌体 miR-29a 能够很好地区分 PTC 与正常对照者。此外，手术后 30 天和 90 天，血清外泌体 miR-29a 水平逐渐显著升高。此外，血清外泌体 miR-29a 表达水平较低的 PTC 患者复发风险较高。血清外泌体 miR-29a 表达降低与肿瘤大小、甲状腺外侵犯和 TNM 分期等更差的临床变量以及较短的生存时间显著相关。最后，单因素和多因素分析均表明血清外泌体 miR-29a 是总生存期的独立预后指标。
这些结果表明，血清外泌体 miR-29a 可能作为 PTC 诊断和预后的潜在生物标志物。
